TrialPath

Find a study

Browse recruiting studies near you — free to check, always your choice.

Match me to a study

89 studies

Recruiting now, in plain language. Every study is watched over by an independent ethics board.

ListMap
Weight & metabolicPeptide & GLP-1Mental healthLungs & breathingHeart & circulationKidneyBrain & memoryBlood disordersImmune & autoimmuneSkin

84 studies on the map

A Long-term Extension (LTE) Study of Guselkumab in Pediatric Participants — Emory University, AtlantaA Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease — Cedars Sinai Medical Center, Los AngelesA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039, Colorado SpringsA Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Del Sol Research Management, LLC - Site Number: 8400012, TucsonEfficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis. — Perseverance Research Center, ScottsdaleStudy to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab — TG Therapeutics Investigational Trial Site, BirminghamAn Open-label Study of AZD0120 in Adults With Multiple Sclerosis — Research Site, TucsonEvaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopic Dermatitis — National Institutes of Health Clinical Center, BethesdaA Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease — Phoenix Children's Hospital, PhoenixA Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases — Stanford Neuroscience Health Center, Palo AltoA Study of Anti-CD19 Chimeric Antigen Receptor T-Cell ( CAR-T) Therapy in Subjects With Non-relapsing and Progressive Forms of Multiple Sclerosis — Stanford Multiple Sclerosis Center, Palo AltoAn Early-Stage Study in Multiple Clinics of How Afimkibart May Affect the Body's Processing of Medicines That Rely on Cytochrome P450 Enzymes in Participants With Ulcerative Colitis — Erick H. Alayo Medical Corporation - Gastro SB Clinic, Chula VistaA Study of the Medicine Called Abrocitinib in Children 6 to Less Than 12 Years of Age With Moderate-to-Severe Eczema — Cahaba Dermatology & Skin Health Center, LLC, BirminghamA Study of BBT001 in Healthy Volunteers (HVs) and in Adult Patients With Atopic Dermatitis (AD) — First OC Dermatology, IrvineA Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PheonixAutologous Stem Cell Transplantation for Crohn's Disease — UPMC Prebyterian- Adult Gastroenterology, PittsburghBest Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS) — Stanford Multiple Sclerosis Center, Palo AltoAn Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab — National Institutes of Health Clinical Center, BethesdaA Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease — UCSD Medical Center, La JollaTesting the Role of Anti-fungal Therapy in Improving the Response to Therapies for Crohn's Disease — Weill Cornell Medicine, New YorkA Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease — Phoenix Children's Hospital /ID# 255766, PhoenixTreatment of Moderate to Severe Refractory Crohn's Disease — Mayo Clinic Arizona, ScottsdalePh 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234 — Clinical Site 101, Fair LawnA Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis — Phoenix Children's Hospital /ID# 273015, PhoenixA Study of Orelabrutinib in Patients With Secondary Progressive Multiple Sclerosis — Arizona Neuroscience Research, LLC, PhoenixA Study to Investigate the Safety, Tolerability, and Processing by the Body of Intravenous and Subcutaneous RO7121932 Administration in Participants With Multiple Sclerosis — Stanford University Medical Center, StanfordStudy to Evaluate the Effectiveness and Safety of Ozanimod Compared to Fingolimod in Children and Adolescents With Relapsing Remitting Multiple Sclerosis — Local Institution - 0114, Loma LindaTreatment of Participants With Primary or Secondary Progressive Multiple Sclerosis — University of Kansas Medical Center, Kansas CityAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis — Onyx Clinical Research - Site Number: 8400021, PeoriaA Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Afimkibart (RO7790121) in Children With Moderately to Severely Active Ulcerative Colitis — Children's Healthcare of Atlanta, AtlantaA Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2) — Local Institution - 0011, BirminghamA Study of Guselkumab Versus Risankizumab in Participants With Moderately to Severely Active Crohn's Disease — Digestive Health Specialists of the Southeast, DothanExploring the Utility of [18F]3F4AP for Demyelination Imaging — Yale University PET Center, New HavenA Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis — Applied Research Center Of Arkansas /ID# 268547, Little RockMirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study — Digestive Health Specialists, DothanMirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight — Digestive Health Specialists, DothanA Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Alabama Neurology Associates PC, BirminghamThe Impact of Botox on Neuroimmune Interactions in Atopic Dermatitis — University of Pittsburgh Medical Center, PittsburghA Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis — AllerVie Clinical Research, BirminghamSafety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis — Red River Research Partners, FargoA Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008) — Digestive Health Specialists ( Site 5064), DothanFIH Study to Evaluate the Tolerability of PF-07832837 in Healthy Adults and Patients — Anaheim Clinical Trials, LLC, AnaheimA Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease — Cedars Sinai Medical Center, Los AngelesA 3-part Study of SYX-5219 in Healthy Volunteers and Participants With Atopic Dermatitis — Sitryx Clinical Site, Arkansas CityR-3750 in Patients With Mild to Moderate Ulcerative Colitis — Amicis Research Center, ValenciaA Study of JNJ-78934804 in Participants With Moderately to Severely Active Crohn's Disease — Clinnova Research, AnaheimA Trial to Evaluate the Efficacy and Safety of Tralokinumab in Combination With Topical Corticosteroids in Children and Infants With Moderate-to-severe Atopic Dermatitis — Leo Pharma Investigational site, BirminghamTargeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2) — University of California, San Diego: Dermatology Clinical Trials Unit, San DiegoCrohn's Disease: Efficacy, Safety, and Pharmacokinetics of Upadacitinib in Pediatric Subjects With Moderately to Severely Active Crohn's Disease — UCSF Benioff Children's Hospital - Oakland /ID# 262217, OaklandBeta-Hydroxybutyrate Feasibility Treating IBD — University of Texas at Austin, AustinStudy of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis — Xencor Investigative Site, ScottsdaleA Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab — Cahaba Dermatology & Skin Health Center /ID# 263855, BirminghamA Long-Term Extension Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis (UC) or Crohn's Disease (CD) — Phoenix Childrens Hospital, PhoenixObe-cel in Refractory Progressive Forms of Multiple Sclerosis — Stanford University, Redwood CityAssessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy — Sandler Neurosciences Building, Neurological Clinical Research Unit, San FranciscoNon-invasive Electrical Spinal Cord Stimulation To Restore Upper Extremity Function in Multiple Sclerosis — University of Washington, SeattleA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic Dermatitis — Nektar Investigative Site, St. PetersburgAn Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease — Onyx Clinical Research - Site Number: 8400021, PeoriaA Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease — AZ Gastro Care, ChandlerA Study to Investigate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamics of a New Subcutaneous Formulation of Ocrelizumab in Participants With Multiple Sclerosis — Profound Research, LLC, CarlsbadAssessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714. — University of Alabama at Birmingham Medical Center, BirminghamA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (Also Known as RO7790121) in Participants With Moderately to Severely Active Ulcerative Colitis — Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, DothanLow Dose IL-2 for the Treatment of Crohn's Disease — Boston Children's Hospital, BostonExtension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011) — Connecticut Clinical Research Institute ( Site 0297), BristolA Study of Vedolizumab in Children and Teenagers With Moderate to Severe Crohn's Disease (CD) — Phoenix Childrens Hospital, PhoenixSafety, PK and Biodistribution of 18F-OP-801 in Patients With ALS, AD, MS, PD and Healthy Volunteers — UCSF, San FranciscoA Study of Vedolizumab in Children With Ulcerative Colitis (UC) or Crohn's Disease (CD) — University of South Alabama (USA) Physicians Group, MobileNon-inferiority Study of Frexalimab Subcutaneous Administration Compared to Intravenous Administration in Adult Participants With Multiple Sclerosis — North Central Neurology Associates- Site Number : 8401100, CullmanStudy to Evaluate the Fecal Microbiota Transplantation (FMT) in the Treatment of Ulcerative Colitis — The University of Texas Health Science Center at Houston, HoustonCentral Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy — National Institutes of Health Clinical Center, BethesdaPET Brain Imaging in Multiple Sclerosis, Alzheimer's Disease, and Other Neurological and Neuropsychiatric Diseases — Brigham MS Center, 60 Fenwood Road, BostonTargeting Residual Activity By Precision, Biomarker-Guided Combination Therapies of Multiple Sclerosis (TRAP-MS) — National Institutes of Health Clinical Center, BethesdaMolecular Imaging of NET Using [C-11]MRB-PET in MS — Brigham MS Center, 60 Fenwood Road, BostonTesting an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVO — University of Alabama at Birmingham Cancer Center, BirminghamPilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy — Connecticut Children's Medical Center, HartfordStem Cell Transplantation in Crohn's Disease — Cedars-Sinai Medical Center, Los AngelesInvestigating the Utility of Demyelination Tracer [18F]3F4AP in Controls and Multiple Sclerosis Subjects — Massachusetts General Hospital, BostonA Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON) — UCSF Medical Center at Mission Bay, San FranciscoVancomycin Study in Multiple Sclerosis (MS) — Corinne Goldsmith Dickinson Center for Multiple Sclerosis at Mount Sinai, New YorkPrecise Infliximab Exposure and Pharmacodynamic Control — Children's Hospital of Los Angeles, Los AngelesA Study to Investigate the Safety, Tolerability, and Efficacy of BxC-I17e Single and Multiple Dose SC Injection in Patients With Moderate to Severe Atopic Dermatitis — Arkansas Research Trials, North Little RockA Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema — Cahaba Dermatology & Skin Health Center, BirminghamA Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Digestive Health Specialists of the Southeast (Gastroenterology Associates of Dothan) - Dothan, DothanA Study to Assess the Efficacy and Safety of Induction Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease — Sun City Clinical Research, Glendale